Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Excision Margin Clear all
Recruiting Phase 1Phase 2 Interventional

Proton or Photon RT for Retroperitoneal Sarcomas

NCT01659203
View directory record Official record
Conditions
Retroperitoneal Sarcoma
Interventions
IG-IMPT, IG IMRT
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
10
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 9, 2026, 11:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CellFX Treat & Resect Low-Risk BCC Feasibility Study

NCT04918381
View directory record Official record
Conditions
BCC - Basal Cell Carcinoma, BCC, Excision Margin
Interventions
CellFX System
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Vestavia Hills, Alabama • Beverly Hills, California • Clearwater, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Jun 9, 2026, 11:50 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma

NCT05656833
View directory record Official record
Conditions
Melasma
Interventions
Fractional 1927nm Low-Powered Diode Laser, Topical Cysteamine
Device · Other
Lead sponsor
UnionDerm
Other
Eligibility
18 Years to 74 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Jun 9, 2026, 11:50 PM EDT
Completed No phase listed Observational

Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade

NCT00972010
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Sarah Blair, M.D.
Other
Eligibility
Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Jun 9, 2026, 11:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of a Universal Adhesive in Noncarious Cervical Lesions

NCT02172664
View directory record Official record
Conditions
Cervical Lesions
Interventions
Self etch enamel etching, selective etch protocol, Adhese Universal
Procedure · Device
Lead sponsor
Indiana University
Other
Eligibility
20 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Jun 9, 2026, 11:50 PM EDT
Completed No phase listed Observational Results available

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)

NCT01699867
View directory record Official record
Conditions
Breast Cancer
Interventions
Optical coherence tomography
Device
Lead sponsor
Diagnostic Photonics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Annapolis, Maryland • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Jun 9, 2026, 11:50 PM EDT
Recruiting Not applicable Interventional

Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma

NCT07060261
View directory record Official record
Conditions
Human Papilloma Virus Related Carcinoma, Tonsillar Squamous Cell Carcinoma
Interventions
Transoral robotic surgery+MRI
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 9, 2026, 11:50 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

NCT01220258
View directory record Official record
Conditions
Posterior Blepharoconjunctivitis
Interventions
Azithromycin ophthalmic solution, 1%
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Jun 9, 2026, 11:50 PM EDT
Completed Phase 1Phase 2 Interventional

Percutaneous Removal and Margin Ablation for Breast Cancer

NCT00574301
View directory record Official record
Conditions
Breast Cancer
Interventions
Percutaneous Removal and Margin Ablation
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Jun 9, 2026, 11:50 PM EDT
Active, not recruiting Not applicable Interventional

A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia

NCT05934851
View directory record Official record
Conditions
Vulvar Neoplasm, Dysplasia Vulvar
Interventions
Frozen-Section Directed Excision, Wide Local Excision
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 9, 2026, 11:50 PM EDT
Terminated Not applicable Interventional

MRI Evaluation of the Breast Areolar Margin and Paryenchyma

NCT01300585
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI
Other
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2014 · Synced Jun 9, 2026, 11:50 PM EDT
Recruiting Phase 1 Interventional

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

NCT07517198
View directory record Official record
Conditions
Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)
Interventions
EXS74539
Drug
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Fort Worth, Texas • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jun 9, 2026, 11:50 PM EDT
Recruiting Phase 1Phase 2 Interventional

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

NCT06239272
View directory record Official record
Conditions
Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Myoepithelioma, Fibrosarcoma NOS, Myxofibrosarcoma, Angiosarcoma, Osteosarcoma, Extraskeletal
Interventions
Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin, Selinexor
Procedure · Radiation · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
6
States / cities
Chicago, Illinois • Baton Rouge, Louisiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 9, 2026, 11:50 PM EDT
Completed Not applicable Interventional

Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery

NCT01646697
View directory record Official record
Conditions
Pancreatic Cancer, Adenocarcinoma
Interventions
cytology specimen collection procedure
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Jun 9, 2026, 11:50 PM EDT
Completed No phase listed Observational

Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection and Evaluation of PSMA-PET for Diagnosis of Intraprostatic Lesions

NCT03213951
View directory record Official record
Conditions
Prostate Cancer
Interventions
Experimental beta probe, PSMA-PET
Other · Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Jun 9, 2026, 11:50 PM EDT
Completed Not applicable Interventional

Evaluation of Breast Cancer Surgical Margins Using Optical Spectroscopy

NCT00214292
View directory record Official record
Conditions
Breast Cancer
Interventions
fluorescence spectroscopy and diffuse spectroscopy
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jun 9, 2026, 11:50 PM EDT
Active, not recruiting Not applicable Interventional

MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

NCT02385214
View directory record Official record
Conditions
Cutaneous Melanoma by AJCC V7 Stage
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jun 9, 2026, 11:50 PM EDT
Completed Phase 2 Interventional Results available

A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer

NCT02159703
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
TORS, Adjuvant Radiation Therapy
Procedure · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jun 9, 2026, 11:50 PM EDT
Recruiting Phase 2 Interventional

Intraoperative Tumor Margin Identification With ICG Dye Imaging

NCT04752137
View directory record Official record
Conditions
Benign Neoplasm, Malignant Neoplasm
Interventions
Indocyanine green, SPY-PHI
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 9, 2026, 11:50 PM EDT
Recruiting Not applicable Interventional

High-Resolution PET-CT Imaging for Surgical Margin Visualization

NCT06915454
View directory record Official record
Conditions
Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Interventions
Intra-op PET/CT Specimen Scanner
Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 9, 2026, 11:50 PM EDT
Recruiting Phase 2 Interventional

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

NCT07132190
View directory record Official record
Conditions
Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
Interventions
Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
Radiation
Lead sponsor
Ayal A. Aizer, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 9, 2026, 11:50 PM EDT
Active, not recruiting Phase 2 Interventional

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

NCT04166318
View directory record Official record
Conditions
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Capecitabine, Computed Tomography, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
659
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 9, 2026, 11:50 PM EDT
Active, not recruiting Phase 2 Interventional

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028
View directory record Official record
Conditions
AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Anoscopy, Biospecimen Collection, Capecitabine, Colonoscopy, Computed Tomography, Digital Rectal Examination, Echocardiography Test, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Lymph Node Biopsy, Magnetic Resonance Imaging, Mitomycin, Nivolumab, Positron Emission Tomography, Proctoscopy, Questionnaire Administration, Sigmoidoscopy
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
14
States / cities
San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 9, 2026, 11:50 PM EDT
Suspended No phase listed Observational

The Impact of Surgeon-Interpreted Intraoperative Margin Assessment During Breast Conserving Surgery on Postoperative Treatment

NCT07140965
View directory record Official record
Conditions
Breast Cancer
Interventions
Pegulicianine Fluorescence-Guided Surgery, Digital Breast Tomosynthesis, Breast Conserving Therapy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 9, 2026, 11:50 PM EDT